Genome-Based Classification and Therapy of Prostate Cancer
AbstractIn the past decade, multi-national and multi-center efforts were launched to sequence prostate cancer genomes, transcriptomes, and epigenomes with the aim of discovering the molecular underpinnings of tumorigenesis, cancer progression, and therapy resistance. Multiple biological markers and pathways have been discovered to be tumor drivers, and a molecular classification of prostate cancer is emerging. Here, we highlight crucial findings of these genome-sequencing projects in localized and advanced disease. We recapitulate the utility and limitations of current clinical practices to diagnosis, prognosis, and therapy, and we provide examples of insights generated by the molecular profiling of tumors. Novel treatment concepts based on these molecular alterations are currently being addressed in clinical trials and will lead to an enhanced implementation of precision medicine strategies. View Full-Text
Share & Cite This Article
Angeles, A.K.; Bauer, S.; Ratz, L.; Klauck, S.M.; Sültmann, H. Genome-Based Classification and Therapy of Prostate Cancer. Diagnostics 2018, 8, 62.
Angeles AK, Bauer S, Ratz L, Klauck SM, Sültmann H. Genome-Based Classification and Therapy of Prostate Cancer. Diagnostics. 2018; 8(3):62.Chicago/Turabian Style
Angeles, Arlou K.; Bauer, Simone; Ratz, Leonie; Klauck, Sabine M.; Sültmann, Holger. 2018. "Genome-Based Classification and Therapy of Prostate Cancer." Diagnostics 8, no. 3: 62.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.